Hmmmmm10 Apr 2022 20:52
According to Richard Pazdur, MD, director of the FDA’s Office of Hematology and Oncology Products and acting director of the FDA’s Oncology Center of Excellence, “This is the first new therapy approved by the FDA for the initial treatment of soft tissue sarcoma since doxorubicin’s approval more than 40 years ago.”
Soft tissue sarcomas arise in soft tissues of the body, such as the muscles, tendons, fat, blood vessels, lymph vessels, nerves, and tissues around joints. They are a rare and diverse group of cancers. In fact, the World Health Organization lists more than 50 subtypes of soft tissue sarcoma and estimates that they account for about 1 percent of all new adult cancers.
Most patients with metastatic soft tissue sarcoma that cannot be removed by surgery are initially treated with doxorubicin, either alone or in combination with other therapeutics. However, new treatments are urgently needed, as a recent study found that just 10 percent of patients were alive five years after starting systemic treatment.